TY - JOUR
T1 - Low visceral fat content is a negative predictive marker for bevacizumab in metastatic colorectal cancer
AU - Miyamoto, Yuji
AU - Oki, Eiji
AU - Emi, Yasunori
AU - Tokunaga, Shoji
AU - Shimokawa, Mototsugu
AU - Ogata, Yutaka
AU - Akagi, Yoshito
AU - Sakamoto, Yasuo
AU - Tanaka, Takaho
AU - Saeki, Hiroshi
AU - Maehara, Yoshihiko
AU - Baba, Hideo
N1 - Funding Information:
EO, YE, YA, YMa and HB received honorarium from Chugai Pharmaceutical Co. Ltd. EO, YA and HB received honorarium from Taiho Yakuhin Co. Ltd. EO and YMa received honorarium from Yakult Honsha Co. Ltd. EO and HB received honorarium from Merk Japan. EO and HB received honorarium from Bayer. EO and YA received honorarium from Takeda Pharmaceutical Co. Ltd. YO, HS, YMa and HB received research funding from Chugai Pharmaceutical Co. Ltd. YMa and HB received research funding from Yakult Honsha Co. Ltd. YMa and Hb received research funding from Taiho Yakuhin Co. Ltd. YMa received research funding from Merk. HB received research funding from Takeda Pharmaceutical Co. Ltd. YMi, ST, MS, YS and TT have no conflict of interest directly relevant to the content of this article.
PY - 2018/1
Y1 - 2018/1
N2 - Aim: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. Results: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). Conclusion: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC.
AB - Aim: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. Results: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). Conclusion: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC.
UR - http://www.scopus.com/inward/record.url?scp=85039776219&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85039776219&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12249
DO - 10.21873/anticanres.12249
M3 - Article
C2 - 29277814
AN - SCOPUS:85039776219
SN - 0250-7005
VL - 38
SP - 491
EP - 499
JO - Anticancer Research
JF - Anticancer Research
IS - 1
ER -
